Nitric oxide (NO) is essential for the normal functioning of the cardiovascular system. This study has determined whether chronic administration of L-arginine, the biological precursor of NO, attenuates the development of structural and functional changes in the hearts and blood vessels of deoxycorticosterone acetate (DOCA)-salt hypertensive rats. Uninephrectomised rats treated with DOCA (25mg every 4th day sc) and 1% NaCl in the drinking water for 4 weeks were treated with L-arginine (5% in food, 3.4±0.3 g/kg body weight/d). Changes in cardiovascular structure and function were determined by echocardiography, microelectrode studies, histology and studies in isolated hearts and thoracic aortic rings. DOCA-salt rats developed hypertension, left ventricular hypertrophy with an increased left ventricular wall thickness and decreased ventricular internal diameter, increased inflammatory cell infiltration, increased ventricular interstitial and perivascular collagen deposition, increased passive diastolic stiffness, prolonged action potential duration, increased oxidative stress and an inability to increase purine efflux in response to an increased workload. Administration of L-arginine markedly attenuated or prevented these changes. L-arginine treatment also normalised the reduced efficacy of noradrenaline and acetylcholine in isolated thoracic aortic rings of DOCA-salt rats. This study suggests that a functional NO deficit in blood vessels and the heart due to decreased NO synthase activity or increased release of reactive oxygen species such as superoxide may be a key change initiating many aspects of the cardiovascular impairment observed in DOCA-salt hypertensive rats. These changes can be prevented or attenuated by administration of L-arginine.
INTRODUCTION
Nitric oxide (NO), essential for the proper functioning of the cardiovascular system, is derived from L-arginine by NO synthase in endothelial cells (35) . NO synthase inhibition produces hypertension, endothelial damage, cardiac hypertrophy, inflammation, atherosclerosis, ventricular contractile dysfunction and fibrosis (20, 24, 31, 35) . Many of these pathophysiological responses are also characteristic of rat models of mineralocorticoid hypertension such as the deoxycorticosterone acetate (DOCA)-salt or aldosterone-salt hypertensive rat (15) , suggesting that decreased NO availability may be a possible mechanism in these models. This is supported by the important role of decreased NO synthase activity in inducing salt-sensitive hypertension in the Dahl rat (37, 42) . Further, there is an increased production of superoxide by NADPH oxidase in aortic rings from DOCA-salt hypertensive rats (11,29.41) . This would also decrease NO availability since superoxide reacts rapidly with NO producing peroxynitrite, possibly inducing further cellular damage.
Administration of L-arginine as a source of NO has already been shown to prevent severe nephrosclerosis, hypertension, hypertrophy and collagen increases in ageing SHR rats (32, 40, 44) while L-arginine prevented the development of hypertension in DOCA-salt rats (27).
This project has determined whether oral administration of L-arginine to DOCA-salt hypertensive rats prevents or attenuates the development of structural and functional changes in the heart and blood vessels. Structural changes were characterised by histology and echocardiography while the function of the heart was measured in vivo using echocardiography and ex vivo in isolated perfused hearts. Single-cell microelectrode recordings from left ventricular papillary muscles were used to determine changes in cardiac action potentials. Isolated thoracic aortic rings have been used to measure vascular reactivity.
EXPERIMENTAL PROCEDURES

DOCA-salt hypertensive rats
Male Wistar rats (8) (9) (10) Uninephrectomy was performed on all treated rats. The rats were anaesthetised with intraperitoneal tiletamine (25 mg/kg) and zolazepam (25 mg/kg)(Zoletil ) together with xylazine (10 mg/kg)(Rompun®); a lateral abdominal incision provided access to the kidney, and the left renal vessels and ureter were ligated. The left kidney was removed and weighed and the incision site sutured. Uninephrectomized rats were given either no further treatment (UNX rats) or 1% NaCl in the drinking water with subcutaneous injections of deoxycorticosterone acetate (DOCA; 25mg in 0.4ml dimethylformamide every fourth day) (DOCA-salt rats) (13) . L-Arginine was administered as a 5% mixture in powdered rat food available ad libitum for 28 days.
Experiments were performed 28 days after surgery as in previous studies (2, 9, 13, 27, 33) .
Assessment of physiological parameters
Food and water intake and body weights were measured daily for all rats. Systolic blood pressure and heart rate were measured in selected rats during light anaesthesia with intraperitoneal Zoletil® (tiletamine 15mg/kg with zolazepam 15mg/kg) using a tail pulse transducer (MLT1010) and an inflatable tail cuff with a Capto SP844 physiological pressure transducer (MLT844/D) connected to a PowerLab data acquisition unit (ADInstruments, Sydney, Australia). Rats were killed with pentobarbitone (200 mg/kg ip). Blood was taken from the abdominal vena cava, centrifuged and the plasma frozen. Following thawing, plasma glucose was measured by Precision Plus Blood Glucose Electrodes (Medisense, Abbott Laboratories); plasma sodium and potassium concentrations were determined by flame photometry; plasma malondialdehyde levels were determined by HPLC (43) .
Echocardiography
Serial, in vivo left parasternal and left apical echocardiographic images of rats were obtained using the Hewlett Packard Sonos 5500 (12MHz frequency fetal transducer)
at an image depth of 3 cm using two focal zones (10) . Rats were anaesthetised as described for uninephrectomy. Left ventricular M-mode measurements at the level of the papillary muscles included left ventricular end-diastolic dimensions, left ventricular end-systolic dimensions, interventricular septum and posterior wall thicknesses and fractional shortening. Cardiac output, ejection fraction and left ventricular mass were derived from these values (30). Pulsed-wave Doppler analyses of mitral valve inflows were used as estimates of diastolic function.
Isolated heart preparations
The non-recirculating heart preparation was used for isolated myocardial experiments (9, 33) . Briefly, following anaesthesia with pentobarbitone sodium (100 mg/kg intraperitoneal) and administration of heparin (1000 IU iv, femoral vein), hearts were rapidly excised and placed in ice-cold modified Krebs-Henseleit buffer containing (in mM): NaCl 119. 
A. Diastolic stiffness
Myocardial diastolic stiffness was defined by the stiffness constant (k, dimensionless) that is the slope of the linear relation between the tangent elastic modulus (E, dyne/cm 2 ) and stress ( , dyne/cm 2 ) as used in previous studies (9, 33) . To assess contractile function, maximal +dP/dt values were calculated at a diastolic pressure of 10 mmHg. At the end of the experiment, the atria were removed and the weight of the ventricles plus septum was recorded.
B. Purine efflux
Following equilibration, hearts were subjected to increased cardiac workloads via bipolar atrial pacing for five minute intervals at 6 and 9 Hz (360 and 540 beats/min).
Contractile function and coronary venous effluent (from the cannulated pulmonary artery) were sampled prior to, and at 4 minutes into the 5-minute pacing episodes (16) . Effluent samples were immediately frozen and stored at -80 o C. HPLC (reverse phase) analysis of samples was performed on a Waters Alliance HPLC using Waters Millenium software. Purines (adenosine, inosine and hypoxanthine) were eluted using a gradient comprising 50mM KH 2 PO 4 / 3% methanol (buffer A) and 50% methanol / water (buffer B) at a constant flow rate of 1mL/min and purine efflux calculated as nmole/min/g wet heart weight.
C. Cardiac energetics
Hearts were perfused with phosphate-free modified Krebs-Henseleit perfusate and then located inside a 20 mm NMR tube and introduced into the center of a 56 mm bore Oxford 400 (9.39T) magnet (16) . A 10-minute equilibration followed, prior to the acquisition of 5-minute 31 P-NMR spectra (110 free induction decays) at the resting (unpaced) heart rate and during 15 minutes of normothermic hypoxia (buffer gassed with 95% N 2 and 5%CO 2 ) and 30 minutes of reperfusion with normal buffer.
Spectral intensities for PCr, -ATP and P i were determined by computer integration using resident VNMR software. Calculations of myocardial ATP and PCr concentrations were performed as described previously (16) .
Microelectrode studies on isolated left ventricular papillary muscles
Rats were anaesthetised by CO 2 inhalation and then euthanased by exsanguination.
The thorax was opened quickly and the heart was removed. After maximum preload was attained, the muscle was allowed to equilibrate for a 
Data analysis
All results are given as mean ± SEM. These results were analyzed by one-way ANOVA with post-hoc comparisons of group means via unpaired or paired t-tests as appropriate; p<0.05 was considered significant.
Drugs
Deoxycorticosterone acetate, L-arginine, heparin, noradrenaline, acetylcholine and sodium nitroprusside were purchased from Sigma Chemical Company, St Louis, MO, USA. L-arginine was thoroughly mixed with ground rat food pellets to a final concentration of 5%. Noradrenaline, acetylcholine and sodium nitroprusside were dissolved in distilled water; 4-aminopyridine was dissolved in 0.01M HCl;
deoxycorticosterone acetate was dissolved in dimethylformamide with mild heating.
RESULTS
DOCA-salt treated uninephrectomied rats developed hypertension (Table 1) and an increased water intake ( Figure 1 ) but failed to significantly gain weight (Figure 2 ). Larginine treatment significantly prevented the increase in systolic blood pressure in DOCA-salt rats (Table 1 ) but failed to alter the body weight or increased water intake (Figures 1 and 2 ). DOCA-salt treatment significantly reduced plasma potassium concentrations but did not alter plasma glucose and sodium concentrations; oral Larginine treatment did not alter these parameters (Table 1) . Plasma malondialdehyde concentrations, as a measure of oxidative stress, were increased following 4 weeks of DOCA-salt hypertension; this increase was prevented by L-arginine treatment ( Table   1 ). Intake of L-arginine calculated from the daily food intake was not significantly different between the treated groups (UNX+L-arginine, 3.6±0.1; DOCA-salt+L-arginine, 3.4±0.3 g/kg body weight/d) ( Figure 3 ).
Hearts from DOCA-salt animals showed marked cardiac hypertrophy as evidenced by both left ventricular wet weights relative to body weight and left ventricular mass derived from echocardiography (Tables 1 and 2 ). This was associated with a 21% decrease in left ventricular internal diameter indicating concentric cardiac hypertrophy (Table 2) . Additionally, the relative wet weights of both the right ventricle and remnant kidney from DOCA-salt treated-rats were increased (Table 1) .
Treatment with L-arginine for 28 days attenuated the increased organ weights of the both ventricles and kidney and reduced the decrease in left ventricular chamber diameter (Tables 1 and 2 ).
The left ventricle of DOCA-salt rats showed marked inflammatory cell infiltration perivascularly, in scar tissue and throughout the interstitium compared to UNX or UNX+L-arginine rats. Scar tissue also contained many inflammatory cells in Larginine treated DOCA-salt rats but there were fewer sites of scarring in the Larginine-treated rats. In addition, interstitial tissue showed fewer inflammatory cells in DOCA-salt+L-arginine rats. The left ventricles from DOCA-salt treated-rats showed a significant increase in collagen content, particularly interstitial collagen, which was partially prevented by administration of L-arginine (Table 1, figure 4 ).
Functionally, diastolic stiffness obtained from the isolated Langendorff heart preparation in DOCA-salt animals was significantly increased (Table 1) . This increase was prevented by oral L-arginine treatment (Table 1) . Furthermore, thoracic aortic wall thicknesses and aortic blood flow velocities were increased by DOCA-salt treatment; L-arginine prevented these vascular changes (Tables 1 and 2 ).
Echocardiographic assessment of heart function showed that L-arginine failed to alter the increased ejection fraction and decreased cardiac output observed in DOCA-salt hypertensive rats ( Table 2 ). The lack of significant improvement in systolic function by L-arginine in vivo was supported by contractility studies on isolated Langendorff hearts. DOCA-salt hearts showed a decreased dP/dt that was unaltered by L-arginine treatment ( Table 1 ). The decreased mitral valve E/A ratio indicated a restrictive filling pattern that was prevented by L-arginine treatment (Table 2 ).
In DOCA-salt hypertensive rat hearts, the action potential duration was markedly increased at 20%, 50% and 90% of repolarization; L-arginine treatment prevented prolongation at 20% and 90% repolarization ( Figure 5 ). However, when challenged (Figures 6a and 6b) .
Assessment of metabolic status of hearts using 31 P-NMR spectroscopy in response to hypoxia-reperfusion showed that L-arginine treatment increased metabolic status at rest (increased ATP, PCr) when compared to UNX and DOCA (Table 3) . Hypoxia led to a rapid reduction in contractile function and high energy phosphates and there was no difference in the rate of fall of ATP, PCr or pH between heart groups during hypoxia (results not shown). Normoxic reperfusion quickly restored metabolite levels in all heart groups, however L-arginine-treated hearts again recovered to higher levels in line with pre-hypoxic values that were mirrored by higher coronary flow rates.
Purine efflux from isolated Langendorff hearts was used as an indicator of metabolic efficiency (ATP breakdown) in response to increased workload. An increase in heart rate from 360 to 540 beats/minute produced an increase in purine efflux in UNX NO is rapidly removed by reaction with superoxide to form the very reactive free radical, peroxynitrite. Aortic rings from DOCA-salt rats showed an increased production of superoxide by NADPH oxidase (11, 29, 41) . This was confirmed in our study by the increased plasma malondialdehyde concentrations that were reduced in L-arginine-treated rats. Thus, the decreased NO availability in DOCA-salt rats could also be a result of this increased oxidative stress in this model of hypertension; Larginine, by increasing NO production, has reduced this stress and any subsequent damage. This is consistent with results showing that a reduction in aortic superoxide production in DOCA-salt hypertensive rats by administration of sesamin, a lignan from sesame oil, was associated with a lowered systolic blood pressure and reduced impairment of endothelium-dependent vascular relaxation (36) .
Although treatment with L-arginine markedly attenuated hypertension in these rats, ventricular hypertrophy was reduced to a lesser extent. In DOCA-salt hypertensive rats, endothelin acting predominantly via endothelin-A receptors is the most likely candidate as the mediator of hypertrophy since selective antagonism of the endothelin-A receptors prevented further ventricular hypertrophy in several rat models of hypertension, including the DOCA-salt rat (2); this mechanism is likely to be unaffected by increased NO concentrations.
The prevention of an excessive deposition of extracellular matrix proteins in the heart, termed cardiac fibrosis, has been studied largely in rat models since fibrosis is a process that is inherently difficult to study in normal human patients. Excessive collagen deposition, principally collagens I and III in the heart, impairs the ability of the ventricle to relax (diastolic dysfunction) and also increases the risk of cardiac arrhythmias (4). Cardiac fibrosis has been defined as either reactive (interstitial and perivascular fibrosis) or reparative (scarring following necrosis) (45); both types occur in the DOCA-salt hypertensive heart (6, 46) . Inhibition of the renin-angiotensinaldosterone system with the ACE inhibitor, captopril, the AT1 receptor antagonist, candesartan, or the aldosterone antagonist, spironolactone (9) shown by the improved response to workload stress imposed by pacing and hypoxia.
Purine efflux during increased workloads in L-arginine-treated hearts returned to the normal levels seen in UNX hearts. L-Arginine treatment increased high energy phosphate levels at rest above that seen in UNX and DOCA hearts and these elevated concentrations were evident post-hypoxia aided by improved coronary flow. An increased release of NO during exercise has been proposed to provide the heart with improved blood flow and metabolite delivery (22); L-arginine treatment may be providing this increase in NO in the NO-deficient DOCA-salt heart.
The increased collagen deposition in DOCA-salt rat hearts was associated with an increased diastolic stiffness as measured in the isolated perfused Langendorff heart preparation. Therelationship between collagen deposition and stiffness is very complex: in the SHR heart, stiffness was correlated with the degree of cross-linking rather than the total collagen content (39) and the alignment of fibres is probably also relevant. Importantly, L-arginine treatment totally prevented the increase in diastolic
stiffness. This observation clearly shows both that the decrease in fibrosis in Larginine-treated DOCA-salt rats has functional significance and that the Larginine/NO system plays an integral role in the pathogenesis of diastolic dysfunction.
Our previous studies have shown that the increased passive stiffness in DOCA-salt hypertensive rats can be attenuated or reversed by inhibition of the renin-angiotensin system by captopril, candesartan or spironolactone or by other compounds such as pirfenidone or amiloride (9, 33) . In summary, many of the cardiac and vascular changes observed in the DOCA-salt hypertensive rat can be prevented or attenuated by treatment with L-arginine. This suggests that a functional NO deficit in blood vessels and the heart due to decreased NO synthase activity or increased release of reactive oxygen species such as superoxide may be a key change initiating many of these cardiovascular impairments. All values shown represent the mean ± SEM. n = number of experiments, LVIDd = left ventricular internal diameter in diastole, LVPWd = left ventricular posterior wall thickness in diastole, E/A = mitral valve flow rate ratio, LV mass = left ventricular mass. Significance -*p < 0.05 vs UNX rats; **p < 0.05 vs DOCA-salt rats. FIGURE 6c
